Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Harvey R Kaslow, PhD

    TitleAssociate Professor of Physiology & Biophysics
    SchoolKeck School of Medicine of USC
    DepartmentPhysiology and Biophysics
    AddressMCH 250 1333 San Pablo Street
    Health Sciences Campus
    Los Angeles California 90089
    Phone+1 323 442 1244
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Recommended URLs:
      http://profiles.sc-ctsi.org/harvey.kaslow
      http://www-hsc.usc.edu/~hrkaslow/

      Main research interest: Cancer Immunotherapy and Regulation of Immune Responses.
      Cytotoxic antibodies and T lymphocytes can be generated that recognize cancer cells, but immunosuppressive factors in solid tumors frequently cause these effectors to fail to control or eliminate the cancer. Compositions are available that overcome these immunosuppressive factors but they produce toxic side-effects which can be life-threatening. There is thus a need for efficacious compositions and methods with reduced toxicity. In collaboration with the laboratory of Alan Epstein (Keck School of Medicine) candidate compositions and methods have been generated and more are under development. Patents covering some compositions and methods have issued and additional patent applications are ongoing and planned. For additional information see
      Cancer Immunotherapy Research:
      http://www-hsc.usc.edu/~hrkaslow/Research/cancerimmunotherapy.html
      Patents http://www-hsc.usc.edu/~hrkaslow/Research/Patents/

      Education Efforts:
      Dr. Kaslow’s graduate (UCSD) work involved endocrinology and metabolism and his post-doctoral (UCSF) research focused on cell signaling mechanisms. His teaching efforts continue in those areas in graduate, medical, and pharmacy courses. Dr. Kaslow serves as:
      Director, MS program in Medical Physiology
      Co-chair of the Endocrinology section of the medical student curriculum.
      Dr. Kaslow actively participates in the continuing refinement and revision of the medical and graduate student curricula and is developing software for the analysis and management of the curriculum.


      Collapse ORNG Applications 
      Collapse Websites
      Collapse Required Scholarly Project Mentor

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Kawamura H, Aswad F, Minagawa M, Malone K, Kaslow H, Koch-Nolte F, Schott WH, Leiter EH, Dennert G. P2X7 receptor-dependent and -independent T cell death is induced by nicotinamide adenine dinucleotide. J Immunol. 2005 Feb 15; 174(4):1971-9. PMID: 15699125.
        View in: PubMed
      2. Zhu Z, Stevenson D, Ritter T, Schechter JE, Mircheff AK, Kaslow H, Trousdale MD. Expression of IL-10 and TNF-inhibitor genes in lacrimal gland epithelial cells suppresses their ability to activate lymphocytes. Cornea. 2002 Mar; 21(2):210-4. PMID: 11862098.
        View in: PubMed
      3. Trousdale MD, Stevenson D, Zhu Z, Kaslow H, Schechter JE, Warren DW, Azzarolo AM, Ritter T, Mircheff AK. Effect of anti-inflammatory cytokines on the activation of lymphocytes by lacrimal gland acinar cells in an autologous mixed cell reaction. Adv Exp Med Biol. 2002; 506(Pt B):789-94. PMID: 12613993.
        View in: PubMed
      4. Guo Z, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow H. Lacrimal gland epithelial cells stimulate proliferation in autologous lymphocyte preparations. Exp Eye Res. 2000 Jul; 71(1):11-22. PMID: 10880272.
        View in: PubMed
      5. Guo Z, Song D, Azzarolo AM, Schechter JE, Warren DW, Wood RL, Mircheff AK, Kaslow H. Autologous lacrimal-lymphoid mixed-cell reactions induce dacryoadenitis in rabbits. Exp Eye Res. 2000 Jul; 71(1):23-31. PMID: 10880273.
        View in: PubMed
      6. Mircheff AK, Gierow JP, Yang T, Zhang J, Wood RL, Azzarolo AM, Warren DW, Zeng H, Guo Z, Kaslow H, Hamm-Alvarez SF, Okamoto CT, Bachmann M. Sjögren's autoimmunity: how perturbation of recognition in endomembrane traffic may provoke pathological recognition at the cell surface. J Mol Recognit. 1998; 11(1-6):40-8. PMID: 10076804.
        View in: PubMed
      7. Kaslow H, Guo Z, Warren DW, Wood RL, Mircheff AK. A method to study induction of autoimmunity in vitro: co-culture of lacrimal cells and autologous immune system cells. Adv Exp Med Biol. 1998; 438:583-9. PMID: 9634940.
        View in: PubMed
      8. Kaslow H. Authors and Editors of the world unite. FASEB J. 1995 Feb; 9(2):291. PMID: 7781934.
        View in: PubMed
      9. Burnette WN, Kaslow H, Moss J. Molecular engineering of cholera toxin. Adv Exp Med Biol. 1995; 371B:1513-8. PMID: 7502847.
        View in: PubMed
      10. Wang J, Nemoto E, Kots AY, Kaslow H, Dennert G. Regulation of cytotoxic T cells by ecto-nicotinamide adenine dinucleotide (NAD) correlates with cell surface GPI-anchored/arginine ADP-ribosyltransferase. J Immunol. 1994 Nov 1; 153(9):4048-58. PMID: 7930612.
        View in: PubMed
      11. Häse CC, Thai LS, Boesman-Finkelstein M, Mar VL, Burnette WN, Kaslow H, Stevens LA, Moss J, Finkelstein RA. Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs. Infect Immun. 1994 Aug; 62(8):3051-7. PMID: 8039872.
        View in: PubMed
      12. Burnette WN, Cieplak W, Kaslow H, Rappuoli R, Tuomanen EI. Recombinant microbial ADP-ribosylating toxins of Bordetella pertussis, Vibrio cholerae, and enterotoxigenic Escherichia coli: structure, function, and toxoid vaccine development. Bioprocess Technol. 1994; 19:185-203. PMID: 7764758.
        View in: PubMed
      13. Sugawara S, Kaslow H, Dennert G. CTX-B inhibits CTL cytotoxicity and cytoskeletal movements. Immunopharmacology. 1993 Sep-Oct; 26(2):93-104. PMID: 8282542.
        View in: PubMed
      14. Kaslow H, Platler BW, Blumberg DA, Cherry JD. Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum. J Clin Microbiol. 1992 Jun; 30(6):1380-7. PMID: 1624552.
        View in: PubMed
      15. Kaslow H, Burns DL. Pertussis toxin and target eukaryotic cells: binding, entry, and activation. FASEB J. 1992 Jun; 6(9):2684-90. PMID: 1612292.
        View in: PubMed
      16. Burnette WN, Mar VL, Platler BW, Schlotterbeck JD, McGinley MD, Stoney KS, Rohde MF, Kaslow H. Site-specific mutagenesis of the catalytic subunit of cholera toxin: substituting lysine for arginine 7 causes loss of activity. Infect Immun. 1991 Nov; 59(11):4266-70. PMID: 1937784.
        View in: PubMed
      17. Kenimer JG, Probst PG, Karpas AB, Burns DL, Kaslow H. Monoclonal antibodies against the enzymatic subunit of both pertussis and cholera toxins. Dev Biol Stand. 1991; 73:133-41. PMID: 1778307.
        View in: PubMed
      18. Kaslow H, Schlotterbeck JD, Gotto J. Evaluation of antibodies elicited by immunization with pertussis toxin. Dev Biol Stand. 1991; 73:143-50. PMID: 1778308.
        View in: PubMed
      19. Burnette WN, Mar VL, Bartley TD, Kaslow H, Cieplak W, Keith JM, Sato H, Burns DL, Arciniega JL, Shahin RD. The molecular engineering of pertussis toxoid. Dev Biol Stand. 1991; 73:75-8. PMID: 1778336.
        View in: PubMed
      20. Kaslow H, Schlotterbeck JD, Kenimer JG. Monoclonal antibodies that inhibit ADP-ribosyltransferase but not NAD-glycohydrolase activity of pertussis toxin. Infect Immun. 1990 Mar; 58(3):746-52. PMID: 2155182.
        View in: PubMed
      21. Bradley DC, Kaslow H. Radiometric assays for glycerol, glucose, and glycogen. Anal Biochem. 1989 Jul; 180(1):11-6. PMID: 2817333.
        View in: PubMed
      22. Kaslow H, Schlotterbeck JD, Mar VL, Burnette WN. Alkylation of cysteine 41, but not cysteine 200, decreases the ADP-ribosyltransferase activity of the S1 subunit of pertussis toxin. J Biol Chem. 1989 Apr 15; 264(11):6386-90. PMID: 2703495.
        View in: PubMed
      23. Burnette WN, Whiteley DW, Mar VL, Burns DL, Kaslow H, Cieplak W, Keith JM, Bartley TD. Developments toward a recombinant pertussis vaccine. Adv Exp Med Biol. 1989; 251:1-7. PMID: 2692423.
        View in: PubMed
      24. Antwi D, Youn JH, Shargill NS, Lesikar DD, Kaslow H. Regulation of glycogen synthase in muscle and adipose tissue during fasting and refeeding. Am J Physiol. 1988 Jun; 254(6 Pt 1):E720-5. PMID: 3132046.
        View in: PubMed
      25. Youn JH, Kaslow H, Bergman RN. Fructose effect to suppress hepatic glycogen degradation. J Biol Chem. 1987 Aug 25; 262(24):11470-7. PMID: 3114246.
        View in: PubMed
      26. Kaslow H, Lesikar DD. Sulfhydryl-alkylating reagents inactivate the NAD glycohydrolase activity of pertussis toxin. Biochemistry. 1987 Jul 14; 26(14):4397-402. PMID: 2822091.
        View in: PubMed
      27. Kaslow H, Lim LK, Moss J, Lesikar DD. Structure-activity analysis of the activation of pertussis toxin. Biochemistry. 1987 Jan 13; 26(1):123-7. PMID: 3030399.
        View in: PubMed
      28. Moss J, Stanley SJ, Watkins PA, Burns DL, Manclark CR, Kaslow H, Hewlett EL. Stimulation of the thiol-dependent ADP-ribosyltransferase and NAD glycohydrolase activities of Bordetella pertussis toxin by adenine nucleotides, phospholipids, and detergents. Biochemistry. 1986 May 6; 25(9):2720-5. PMID: 2872921.
        View in: PubMed
      29. Kaslow H, Lesikar DD, Antwi D, Tan AW. L-type glycogen synthase. Tissue distribution and electrophoretic mobility. J Biol Chem. 1985 Aug 25; 260(18):9953-6. PMID: 3926776.
        View in: PubMed
      30. Lim LK, Sekura RD, Kaslow H. Adenine nucleotides directly stimulate pertussis toxin. J Biol Chem. 1985 Mar 10; 260(5):2585-8. PMID: 2982826.
        View in: PubMed
      31. Kaslow H, Eichner RD. Fasting and diabetes alter adipose tissue glycogen synthase. Am J Physiol. 1984 Nov; 247(5 Pt 1):E581-4. PMID: 6437248.
        View in: PubMed
      32. Kaslow H, Lesikar DD. Isozymes of glycogen synthase. FEBS Lett. 1984 Jul 9; 172(2):294-8. PMID: 6430719.
        View in: PubMed
      33. Bourne HR, Brothers VM, Kaslow H, Groppi V, Walker N, Steinberg F. Genetic analysis of cyclic nucleotide phosphodiesterases in S49 mouse lymphoma cells. Adv Cyclic Nucleotide Protein Phosphorylation Res. 1984; 16:185-94. PMID: 6326523.
        View in: PubMed
      34. Kaslow H, Garrison CR. A direct radioassay for pyruvate kinase activity. Anal Biochem. 1983 Oct 15; 134(2):495-8. PMID: 6418026.
        View in: PubMed
      35. Groppi VE, Steinberg F, Kaslow H, Walker N, Bourne HR. Identification by direct photoaffinity labeling of an altered phosphodiesterase in a mutant S49 lymphoma cell. J Biol Chem. 1983 Aug 25; 258(16):9717-23. PMID: 6309783.
        View in: PubMed
      36. Kaslow H, Groppi VE, Abood ME, Bourne HR. Cholera toxin can catalyze ADP-ribosylation of cytoskeletal proteins. J Cell Biol. 1981 Nov; 91(2 Pt 1):410-3. PMID: 7309789.
        View in: PubMed
      37. Bourne HR, Kaslow H, Brickman AS, Farfel Z. Fibroblast defect in pseudohypoparathyroidism, type I: reduced activity of receptor-cyclase coupling protein. J Clin Endocrinol Metab. 1981 Sep; 53(3):636-40. PMID: 6267099.
        View in: PubMed
      38. Bourne HR, Kaslow D, Kaslow H, Salomon MR, Licko V. Hormone-sensitive adenylate cyclase. Mutant phenotype with normally regulated beta-adrenergic receptors uncoupled with catalytic adenylate cyclase. Mol Pharmacol. 1981 Sep; 20(2):435-41. PMID: 6272096.
        View in: PubMed
      39. Kaslow H, Cox D, Groppi VE, Bourne HR. An Mr = 52,000 peptide can mediate effects on cholera toxin on adenylate cyclase in intact cells. Mol Pharmacol. 1981 May; 19(3):406-10. PMID: 6790933.
        View in: PubMed
      40. Bourne HR, Farfel Z, Brickman AS, Kaslow H, Brothers VM. Human mutation affecting hormone-sensitive adenylate cyclase. Prog Clin Biol Res. 1981; 63:433-7. PMID: 6273928.
        View in: PubMed
      41. Kaslow H. Apparent phosphorylation of glycogen synthase in mammalian cells lacking cyclic AMP-dependent protein kinase. FEBS Lett. 1980 Aug 11; 117(1):219-23. PMID: 6773808.
        View in: PubMed
      42. Farfel Z, Brickman AS, Kaslow H, Brothers VM, Bourne HR. Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med. 1980 Jul 31; 303(5):237-42. PMID: 6247654.
        View in: PubMed
      43. Kaslow H, Johnson GL, Brothers VM, Bourne HR. A regulatory component of adenylate cyclase from human erythrocyte membranes. J Biol Chem. 1980 Apr 25; 255(8):3736-41. PMID: 7364766.
        View in: PubMed
      44. Johnson GL, Kaslow H, Farfel Z, Bourne HR. Genetic analysis of hormone-sensitive adenylate cyclase. Adv Cyclic Nucleotide Res. 1980; 13:1-37. PMID: 6251703.
        View in: PubMed
      45. Farfel Z, Kaslow H, Bourne HR. A regulatory component of adenylate cyclase is located on the inner surface of human erythrocyte membranes. Biochem Biophys Res Commun. 1979 Oct 29; 90(4):1237-41. PMID: 518596.
        View in: PubMed
      46. Kaslow H, Eichner RD, Mayer SE. Interconversion between multiple glucose 6-phosphate-dependent forms of glycogen synthase in intact adipose tissue. J Biol Chem. 1979 Jun 10; 254(11):4674-7. PMID: 108279.
        View in: PubMed
      47. Kaslow H, Mayer SE. Adaptations of glycogen metabolism in rat epididymal adipose tissue during fasting and refeeding. J Biol Chem. 1979 Jun 10; 254(11):4678-83. PMID: 108280.
        View in: PubMed
      48. Kaslow H, Farfel Z, Johnson GL, Bourne HR. Adenylate cyclase assembled in vitro: cholera toxin substrates determine different patterns of regulation by isoproterenol and guanosine 5'-triphosphate. Mol Pharmacol. 1979 May; 15(3):472-83. PMID: 226858.
        View in: PubMed
      49. Johnson GL, Kaslow H, Bourne HR. Genetic evidence that cholera toxin substrates are regulatory components of adenylate cyclase. J Biol Chem. 1978 Oct 25; 253(20):7120-3. PMID: 212417.
        View in: PubMed
      50. Johnson GL, Kaslow H, Bourne HR. Reconstitution of cholera toxin-activated adenylate cyclase. Proc Natl Acad Sci U S A. 1978 Jul; 75(7):3113-7. PMID: 277913.
        View in: PubMed
      51. Ramseyer J, Kaslow H, Gill GN. Purification of the cAMP receptor protein by affinity chromatography. Biochem Biophys Res Commun. 1974 Jul 24; 59(2):813-21. PMID: 4369094.
        View in: PubMed